Get notified of page updates
Enroll in Research > Research Search & Enroll Tool > Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer (MOUNTAINEER)
Glossary on
off
Printer Friendly Page Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer (MOUNTAINEER)

Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer (MOUNTAINEER)

Clinicaltrials.gov identifier:
NCT03043313


Study Contact Information:

For more information, contact Seagen Trial Information Support at 866-333-7436 or by email. 

Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer (MOUNTAINEER)

About the Study

This is a study for people who have been diagnosed with (HER2+) colorectal cancer (mCRC).  The goal of this study is to look at how well the drug tucatinib (Tukysa) works to improve outcomes when given with trastuzumab (Herceptin), versus how well tucatinib works when administered by itself. NOTE: This study is no longer enrolling patients. 

This Study is Open To:

NOTE: This study is no longer enrolling patients. 

This Study is Not Open To: